CANARX's Arrest Removes America's Drug-Discount Ceiling: 100 Imported Claims in 2024, One Federal Case, and Who Reprices Now

On Sunday, Nov. 8, 2026, federal agents arrested John Thomas Howard, CANARX's treasurer and director, on smuggling and conspiracy charges covering a nine-year course of conduct running from Feb. 22, 2017 to April 15, 2026. The case converts a sixteen-year regulatory file into a federal criminal case, and his brother Bob Howard, CANARX's president and director, remains wanted. CANARX, founded in 2002 in Windsor, Ontario, bills itself as \"the first international prescription provider for the U.S.\" and says its shipments are lawful; general counsel Joseph Morris says the Howards deny all charges and will defend them vigorously.

The volume on the record looks almost embarrassing: more than 100 imported claims in a year at one carve-out PBM, against a US specialty market where Gilead Sciences alone did $29.44 billion of revenue in FY2025. That is the part most investors will misread. The channel's output is trivial while its output price is not: an employer who can tell a PBM that an imported version exists changes the negotiation before a single pill is bought, and the branded price it defends becomes the reference point for every other specialty drug on the same formulary.

What changed is not the statute book but the number of doors being knocked on. FDA's letters reached one company; the Fourth Circuit's injunction reached the referral architecture that converts a plan carve-out into an import order; a federal complaint reaches the officers who sign the invoices. The economics underneath never moved - in 2025 CNBC documented patients being flown to the Cayman Islands to retrieve Biogen's Avonex, which retails in the US at $2,159 per weekly dose.

Read that ranking against the event and the structure is visible. The two companies whose economics are set by US branded pricing policy - Gilead Sciences and Pfizer - sit on opposite sides of it, while the fastest grower in the group, Hims & Hers Health, is a cash-pay channel whose revenue is bought with marketing spend of $247.3M in Q3 FY2026, 27.8% of sales, against a quarterly net loss of $33.0M. Import enforcement changes discount policy rather than demand, so this is a relative-pricing trade inside the sector, not a volume trade.

The cheapest prescription channel in America was never really about prescriptions. It was about a number: the price a plan sponsor could point at when a PBM said the specialty drug was not negotiable. Criminalising the channel removes that number without touching a single US script, which is why the read-through runs to discount policy and brand protection rather than to dispensing volume, and why the names that matter are Gilead Sciences and Pfizer rather than the platforms that merely fill the prescription.